Pharma & Healthcare
Global Non-oncology Biopharmaceuticals Market Insights, Forecast to 2030
- Mar 07, 25
- ID: 1898
- Pages: 129
- Figures: 154
- Views: 21
Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.
Market Analysis and Insights: Global Non-oncology Biopharmaceuticals Market
The global Non-oncology Biopharmaceuticals market is projected to grow from US$ 329360 million in 2024 to US$ 531430 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period.
The US & Canada market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva and Eli Lilly, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Non-oncology Biopharmaceuticals is widely used in various fields, such as Immunology, Endocrinology and Others,, etc. Immunology provides greatest supports to the Non-oncology Biopharmaceuticals industry development. In 2023, global % revenue of Non-oncology Biopharmaceuticals went into Immunology filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Non-oncology Biopharmaceuticals market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Non-oncology Biopharmaceuticals, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non-oncology Biopharmaceuticals, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-oncology Biopharmaceuticals revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Non-oncology Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Non-oncology Biopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
Segment by Type
Biologics
Biosimilars
Segment by Application
Immunology
Endocrinology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Non-oncology Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-oncology Biopharmaceuticals companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-oncology Biopharmaceuticals revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Market Analysis and Insights: Global Non-oncology Biopharmaceuticals Market
The global Non-oncology Biopharmaceuticals market is projected to grow from US$ 329360 million in 2024 to US$ 531430 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period.
The US & Canada market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva and Eli Lilly, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Non-oncology Biopharmaceuticals is widely used in various fields, such as Immunology, Endocrinology and Others,, etc. Immunology provides greatest supports to the Non-oncology Biopharmaceuticals industry development. In 2023, global % revenue of Non-oncology Biopharmaceuticals went into Immunology filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Non-oncology Biopharmaceuticals market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Non-oncology Biopharmaceuticals, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non-oncology Biopharmaceuticals, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-oncology Biopharmaceuticals revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Non-oncology Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Non-oncology Biopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
Segment by Type
Biologics
Biosimilars
Segment by Application
Immunology
Endocrinology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Non-oncology Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-oncology Biopharmaceuticals companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-oncology Biopharmaceuticals revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2019-2030)
2.2 Global Non-oncology Biopharmaceuticals Growth Trends by Region
2.2.1 Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2019-2024)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030)
2.3 Non-oncology Biopharmaceuticals Market Dynamics
2.3.1 Non-oncology Biopharmaceuticals Industry Trends
2.3.2 Non-oncology Biopharmaceuticals Market Drivers
2.3.3 Non-oncology Biopharmaceuticals Market Challenges
2.3.4 Non-oncology Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Non-oncology Biopharmaceuticals by Players
3.1.1 Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2019-2024)
3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Non-oncology Biopharmaceuticals, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2023
3.5 Global Key Players of Non-oncology Biopharmaceuticals Head office and Area Served
3.6 Global Key Players of Non-oncology Biopharmaceuticals, Product and Application
3.7 Global Key Players of Non-oncology Biopharmaceuticals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-oncology Biopharmaceuticals Breakdown Data by Type
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2019-2024)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application
5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2019-2024)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2019-2030)
6.2 North America Non-oncology Biopharmaceuticals Market Size by Type
6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
6.2.3 North America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Application
6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
6.3.3 North America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
6.4 North America Non-oncology Biopharmaceuticals Market Size by Country
6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)
6.4.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2019-2030)
7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type
7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
7.2.3 Europe Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application
7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
7.3.3 Europe Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country
7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)
7.4.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Non-oncology Biopharmaceuticals Market Size (2019-2030)
8.2 China Non-oncology Biopharmaceuticals Market Size by Type
8.2.1 China Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
8.2.2 China Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
8.2.3 China Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
8.3 China Non-oncology Biopharmaceuticals Market Size by Application
8.3.1 China Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
8.3.2 China Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
8.3.3 China Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Non-oncology Biopharmaceuticals Market Size (2019-2030)
9.2 Asia Non-oncology Biopharmaceuticals Market Size by Type
9.2.1 Asia Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
9.2.2 Asia Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
9.2.3 Asia Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
9.3 Asia Non-oncology Biopharmaceuticals Market Size by Application
9.3.1 Asia Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
9.3.2 Asia Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
9.3.3 Asia Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
9.4 Asia Non-oncology Biopharmaceuticals Market Size by Region
9.4.1 Asia Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Non-oncology Biopharmaceuticals Market Size by Region (2019-2024)
9.4.3 Asia Non-oncology Biopharmaceuticals Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type
10.2.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application
10.3.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country
10.4.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.1.5 Roche Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.2.5 Sanofi Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.3.5 Johnson & Johnson Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.4.5 Pfizer Recent Developments
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Details
11.5.2 Novo Nordisk Business Overview
11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.5.5 Novo Nordisk Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.6.5 Novartis Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.7.5 Merck Recent Developments
11.8 Teva
11.8.1 Teva Company Details
11.8.2 Teva Business Overview
11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.8.5 Teva Recent Developments
11.9 Eli Lilly
11.9.1 Eli Lilly Company Details
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.9.5 Eli Lilly Recent Developments
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.10.5 Bristol-Myers Squibb Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.11.5 GlaxoSmithKline Recent Developments
11.12 UCB Pharma
11.12.1 UCB Pharma Company Details
11.12.2 UCB Pharma Business Overview
11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.12.5 UCB Pharma Recent Developments
11.13 Amgen
11.13.1 Amgen Company Details
11.13.2 Amgen Business Overview
11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.13.5 Amgen Recent Developments
11.14 AbbVie
11.14.1 AbbVie Company Details
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.14.5 AbbVie Recent Developments
11.15 Takeda
11.15.1 Takeda Company Details
11.15.2 Takeda Business Overview
11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.15.5 Takeda Recent Developments
11.16 AstraZeneca
11.16.1 AstraZeneca Company Details
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.16.5 AstraZeneca Recent Developments
11.17 Mylan
11.17.1 Mylan Company Details
11.17.2 Mylan Business Overview
11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.17.5 Mylan Recent Developments
11.18 LEO Pharma
11.18.1 LEO Pharma Company Details
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.18.5 LEO Pharma Recent Developments
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Details
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.19.5 Boehringer Ingelheim Recent Developments
11.20 Alexion Pharmaceuticals
11.20.1 Alexion Pharmaceuticals Company Details
11.20.2 Alexion Pharmaceuticals Business Overview
11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.20.5 Alexion Pharmaceuticals Recent Developments
11.21 Elusys Therapeutics
11.21.1 Elusys Therapeutics Company Details
11.21.2 Elusys Therapeutics Business Overview
11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.21.5 Elusys Therapeutics Recent Developments
11.22 Swedish Orphan Biovitrum
11.22.1 Swedish Orphan Biovitrum Company Details
11.22.2 Swedish Orphan Biovitrum Business Overview
11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.22.5 Swedish Orphan Biovitrum Recent Developments
11.23 Biogen
11.23.1 Biogen Company Details
11.23.2 Biogen Business Overview
11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.23.5 Biogen Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2019-2030)
2.2 Global Non-oncology Biopharmaceuticals Growth Trends by Region
2.2.1 Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2019-2024)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030)
2.3 Non-oncology Biopharmaceuticals Market Dynamics
2.3.1 Non-oncology Biopharmaceuticals Industry Trends
2.3.2 Non-oncology Biopharmaceuticals Market Drivers
2.3.3 Non-oncology Biopharmaceuticals Market Challenges
2.3.4 Non-oncology Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Non-oncology Biopharmaceuticals by Players
3.1.1 Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2019-2024)
3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Non-oncology Biopharmaceuticals, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2023
3.5 Global Key Players of Non-oncology Biopharmaceuticals Head office and Area Served
3.6 Global Key Players of Non-oncology Biopharmaceuticals, Product and Application
3.7 Global Key Players of Non-oncology Biopharmaceuticals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-oncology Biopharmaceuticals Breakdown Data by Type
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2019-2024)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application
5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2019-2024)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2019-2030)
6.2 North America Non-oncology Biopharmaceuticals Market Size by Type
6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
6.2.3 North America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Application
6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
6.3.3 North America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
6.4 North America Non-oncology Biopharmaceuticals Market Size by Country
6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)
6.4.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2019-2030)
7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type
7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
7.2.3 Europe Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application
7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
7.3.3 Europe Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country
7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)
7.4.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Non-oncology Biopharmaceuticals Market Size (2019-2030)
8.2 China Non-oncology Biopharmaceuticals Market Size by Type
8.2.1 China Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
8.2.2 China Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
8.2.3 China Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
8.3 China Non-oncology Biopharmaceuticals Market Size by Application
8.3.1 China Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
8.3.2 China Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
8.3.3 China Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Non-oncology Biopharmaceuticals Market Size (2019-2030)
9.2 Asia Non-oncology Biopharmaceuticals Market Size by Type
9.2.1 Asia Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
9.2.2 Asia Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
9.2.3 Asia Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
9.3 Asia Non-oncology Biopharmaceuticals Market Size by Application
9.3.1 Asia Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
9.3.2 Asia Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
9.3.3 Asia Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
9.4 Asia Non-oncology Biopharmaceuticals Market Size by Region
9.4.1 Asia Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Non-oncology Biopharmaceuticals Market Size by Region (2019-2024)
9.4.3 Asia Non-oncology Biopharmaceuticals Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type
10.2.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application
10.3.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country
10.4.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.1.5 Roche Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.2.5 Sanofi Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.3.5 Johnson & Johnson Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.4.5 Pfizer Recent Developments
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Details
11.5.2 Novo Nordisk Business Overview
11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.5.5 Novo Nordisk Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.6.5 Novartis Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.7.5 Merck Recent Developments
11.8 Teva
11.8.1 Teva Company Details
11.8.2 Teva Business Overview
11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.8.5 Teva Recent Developments
11.9 Eli Lilly
11.9.1 Eli Lilly Company Details
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.9.5 Eli Lilly Recent Developments
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.10.5 Bristol-Myers Squibb Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.11.5 GlaxoSmithKline Recent Developments
11.12 UCB Pharma
11.12.1 UCB Pharma Company Details
11.12.2 UCB Pharma Business Overview
11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.12.5 UCB Pharma Recent Developments
11.13 Amgen
11.13.1 Amgen Company Details
11.13.2 Amgen Business Overview
11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.13.5 Amgen Recent Developments
11.14 AbbVie
11.14.1 AbbVie Company Details
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.14.5 AbbVie Recent Developments
11.15 Takeda
11.15.1 Takeda Company Details
11.15.2 Takeda Business Overview
11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.15.5 Takeda Recent Developments
11.16 AstraZeneca
11.16.1 AstraZeneca Company Details
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.16.5 AstraZeneca Recent Developments
11.17 Mylan
11.17.1 Mylan Company Details
11.17.2 Mylan Business Overview
11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.17.5 Mylan Recent Developments
11.18 LEO Pharma
11.18.1 LEO Pharma Company Details
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.18.5 LEO Pharma Recent Developments
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Details
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.19.5 Boehringer Ingelheim Recent Developments
11.20 Alexion Pharmaceuticals
11.20.1 Alexion Pharmaceuticals Company Details
11.20.2 Alexion Pharmaceuticals Business Overview
11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.20.5 Alexion Pharmaceuticals Recent Developments
11.21 Elusys Therapeutics
11.21.1 Elusys Therapeutics Company Details
11.21.2 Elusys Therapeutics Business Overview
11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.21.5 Elusys Therapeutics Recent Developments
11.22 Swedish Orphan Biovitrum
11.22.1 Swedish Orphan Biovitrum Company Details
11.22.2 Swedish Orphan Biovitrum Business Overview
11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.22.5 Swedish Orphan Biovitrum Recent Developments
11.23 Biogen
11.23.1 Biogen Company Details
11.23.2 Biogen Business Overview
11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)
11.23.5 Biogen Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Global Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2019-2024)
Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2025-2030)
Table 10. Non-oncology Biopharmaceuticals Market Trends
Table 11. Non-oncology Biopharmaceuticals Market Drivers
Table 12. Non-oncology Biopharmaceuticals Market Challenges
Table 13. Non-oncology Biopharmaceuticals Market Restraints
Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2019-2024)
Table 16. Global Top Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)
Table 17. Global Non-oncology Biopharmaceuticals Industry Ranking 2022 VS 2023 VS 2024
Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Non-oncology Biopharmaceuticals, Headquarters and Area Served
Table 20. Global Key Players of Non-oncology Biopharmaceuticals, Product and Application
Table 21. Global Key Players of Non-oncology Biopharmaceuticals, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2019-2024)
Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2025-2030)
Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2019-2024)
Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2025-2030)
Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 35. North America Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 42. Europe Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 45. China Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 46. China Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 47. China Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 48. China Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 49. Asia Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 50. Asia Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 51. Asia Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 52. Asia Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 53. Asia Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 54. Asia Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)
Table 55. Asia Non-oncology Biopharmaceuticals Market Size by Region (2025-2030) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 61. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 63. Roche Company Details
Table 64. Roche Business Overview
Table 65. Roche Non-oncology Biopharmaceuticals Product
Table 66. Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 67. Roche Recent Developments
Table 68. Sanofi Company Details
Table 69. Sanofi Business Overview
Table 70. Sanofi Non-oncology Biopharmaceuticals Product
Table 71. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 72. Sanofi Recent Developments
Table 73. Johnson & Johnson Company Details
Table 74. Johnson & Johnson Business Overview
Table 75. Johnson & Johnson Non-oncology Biopharmaceuticals Product
Table 76. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 77. Johnson & Johnson Recent Developments
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer Non-oncology Biopharmaceuticals Product
Table 81. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 82. Pfizer Recent Developments
Table 83. Novo Nordisk Company Details
Table 84. Novo Nordisk Business Overview
Table 85. Novo Nordisk Non-oncology Biopharmaceuticals Product
Table 86. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 87. Novo Nordisk Recent Developments
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Non-oncology Biopharmaceuticals Product
Table 91. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 92. Novartis Recent Developments
Table 93. Merck Company Details
Table 94. Merck Business Overview
Table 95. Merck Non-oncology Biopharmaceuticals Product
Table 96. Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 97. Merck Recent Developments
Table 98. Teva Company Details
Table 99. Teva Business Overview
Table 100. Teva Non-oncology Biopharmaceuticals Product
Table 101. Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 102. Teva Recent Developments
Table 103. Eli Lilly Company Details
Table 104. Eli Lilly Business Overview
Table 105. Eli Lilly Non-oncology Biopharmaceuticals Product
Table 106. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 107. Eli Lilly Recent Developments
Table 108. Bristol-Myers Squibb Company Details
Table 109. Bristol-Myers Squibb Business Overview
Table 110. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
Table 111. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 112. Bristol-Myers Squibb Recent Developments
Table 113. GlaxoSmithKline Company Details
Table 114. GlaxoSmithKline Business Overview
Table 115. GlaxoSmithKline Non-oncology Biopharmaceuticals Product
Table 116. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 117. GlaxoSmithKline Recent Developments
Table 118. UCB Pharma Company Details
Table 119. UCB Pharma Business Overview
Table 120. UCB Pharma Non-oncology Biopharmaceuticals Product
Table 121. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 122. UCB Pharma Recent Developments
Table 123. Amgen Company Details
Table 124. Amgen Business Overview
Table 125. Amgen Non-oncology Biopharmaceuticals Product
Table 126. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 127. Amgen Recent Developments
Table 128. AbbVie Company Details
Table 129. AbbVie Business Overview
Table 130. AbbVie Non-oncology Biopharmaceuticals Product
Table 131. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 132. AbbVie Recent Developments
Table 133. Takeda Company Details
Table 134. Takeda Business Overview
Table 135. Takeda Non-oncology Biopharmaceuticals Product
Table 136. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 137. Takeda Recent Developments
Table 138. AstraZeneca Company Details
Table 139. AstraZeneca Business Overview
Table 140. AstraZeneca Non-oncology Biopharmaceuticals Product
Table 141. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 142. AstraZeneca Recent Developments
Table 143. Mylan Company Details
Table 144. Mylan Business Overview
Table 145. Mylan Non-oncology Biopharmaceuticals Product
Table 146. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 147. Mylan Recent Developments
Table 148. LEO Pharma Company Details
Table 149. LEO Pharma Business Overview
Table 150. LEO Pharma Non-oncology Biopharmaceuticals Product
Table 151. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 152. LEO Pharma Recent Developments
Table 153. Boehringer Ingelheim Company Details
Table 154. Boehringer Ingelheim Business Overview
Table 155. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product
Table 156. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 157. Boehringer Ingelheim Recent Developments
Table 158. Alexion Pharmaceuticals Company Details
Table 159. Alexion Pharmaceuticals Business Overview
Table 160. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product
Table 161. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 162. Alexion Pharmaceuticals Recent Developments
Table 163. Elusys Therapeutics Company Details
Table 164. Elusys Therapeutics Business Overview
Table 165. Elusys Therapeutics Non-oncology Biopharmaceuticals Product
Table 166. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 167. Elusys Therapeutics Recent Developments
Table 168. Swedish Orphan Biovitrum Company Details
Table 169. Swedish Orphan Biovitrum Business Overview
Table 170. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product
Table 171. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 172. Swedish Orphan Biovitrum Recent Developments
Table 173. Biogen Company Details
Table 174. Biogen Business Overview
Table 175. Biogen Non-oncology Biopharmaceuticals Product
Table 176. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 177. Biogen Recent Developments
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Non-oncology Biopharmaceuticals Market Share by Type: 2023 VS 2030
Figure 3. Biologics Features
Figure 4. Biosimilars Features
Figure 5. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Application: 2023 VS 2030
Figure 7. Immunology Case Studies
Figure 8. Endocrinology Case Studies
Figure 9. Others Case Studies
Figure 10. Non-oncology Biopharmaceuticals Report Years Considered
Figure 11. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Region: 2023 VS 2030
Figure 14. Global Non-oncology Biopharmaceuticals Market Share by Players in 2023
Figure 15. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2023
Figure 17. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 19. North America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 20. North America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)
Figure 21. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 24. Europe Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 25. Europe Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 26. Europe Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)
Figure 27. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. China Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 34. China Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 35. China Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 36. Asia Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 37. Asia Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 38. Asia Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 39. Asia Non-oncology Biopharmaceuticals Market Share by Region (2019-2030)
Figure 40. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. China Taiwan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 48. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 49. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)
Figure 50. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Israel Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. GCC Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 57. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 58. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 59. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 60. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 61. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 62. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 63. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 64. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 67. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 68. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 69. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 70. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 71. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 72. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 73. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 74. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 75. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 76. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 77. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 78. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Global Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2019-2024)
Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2025-2030)
Table 10. Non-oncology Biopharmaceuticals Market Trends
Table 11. Non-oncology Biopharmaceuticals Market Drivers
Table 12. Non-oncology Biopharmaceuticals Market Challenges
Table 13. Non-oncology Biopharmaceuticals Market Restraints
Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2019-2024)
Table 16. Global Top Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)
Table 17. Global Non-oncology Biopharmaceuticals Industry Ranking 2022 VS 2023 VS 2024
Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Non-oncology Biopharmaceuticals, Headquarters and Area Served
Table 20. Global Key Players of Non-oncology Biopharmaceuticals, Product and Application
Table 21. Global Key Players of Non-oncology Biopharmaceuticals, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2019-2024)
Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2025-2030)
Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2019-2024)
Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2025-2030)
Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 35. North America Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 42. Europe Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 45. China Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 46. China Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 47. China Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 48. China Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 49. Asia Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 50. Asia Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 51. Asia Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 52. Asia Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 53. Asia Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 54. Asia Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)
Table 55. Asia Non-oncology Biopharmaceuticals Market Size by Region (2025-2030) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 61. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 63. Roche Company Details
Table 64. Roche Business Overview
Table 65. Roche Non-oncology Biopharmaceuticals Product
Table 66. Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 67. Roche Recent Developments
Table 68. Sanofi Company Details
Table 69. Sanofi Business Overview
Table 70. Sanofi Non-oncology Biopharmaceuticals Product
Table 71. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 72. Sanofi Recent Developments
Table 73. Johnson & Johnson Company Details
Table 74. Johnson & Johnson Business Overview
Table 75. Johnson & Johnson Non-oncology Biopharmaceuticals Product
Table 76. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 77. Johnson & Johnson Recent Developments
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer Non-oncology Biopharmaceuticals Product
Table 81. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 82. Pfizer Recent Developments
Table 83. Novo Nordisk Company Details
Table 84. Novo Nordisk Business Overview
Table 85. Novo Nordisk Non-oncology Biopharmaceuticals Product
Table 86. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 87. Novo Nordisk Recent Developments
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Non-oncology Biopharmaceuticals Product
Table 91. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 92. Novartis Recent Developments
Table 93. Merck Company Details
Table 94. Merck Business Overview
Table 95. Merck Non-oncology Biopharmaceuticals Product
Table 96. Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 97. Merck Recent Developments
Table 98. Teva Company Details
Table 99. Teva Business Overview
Table 100. Teva Non-oncology Biopharmaceuticals Product
Table 101. Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 102. Teva Recent Developments
Table 103. Eli Lilly Company Details
Table 104. Eli Lilly Business Overview
Table 105. Eli Lilly Non-oncology Biopharmaceuticals Product
Table 106. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 107. Eli Lilly Recent Developments
Table 108. Bristol-Myers Squibb Company Details
Table 109. Bristol-Myers Squibb Business Overview
Table 110. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
Table 111. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 112. Bristol-Myers Squibb Recent Developments
Table 113. GlaxoSmithKline Company Details
Table 114. GlaxoSmithKline Business Overview
Table 115. GlaxoSmithKline Non-oncology Biopharmaceuticals Product
Table 116. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 117. GlaxoSmithKline Recent Developments
Table 118. UCB Pharma Company Details
Table 119. UCB Pharma Business Overview
Table 120. UCB Pharma Non-oncology Biopharmaceuticals Product
Table 121. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 122. UCB Pharma Recent Developments
Table 123. Amgen Company Details
Table 124. Amgen Business Overview
Table 125. Amgen Non-oncology Biopharmaceuticals Product
Table 126. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 127. Amgen Recent Developments
Table 128. AbbVie Company Details
Table 129. AbbVie Business Overview
Table 130. AbbVie Non-oncology Biopharmaceuticals Product
Table 131. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 132. AbbVie Recent Developments
Table 133. Takeda Company Details
Table 134. Takeda Business Overview
Table 135. Takeda Non-oncology Biopharmaceuticals Product
Table 136. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 137. Takeda Recent Developments
Table 138. AstraZeneca Company Details
Table 139. AstraZeneca Business Overview
Table 140. AstraZeneca Non-oncology Biopharmaceuticals Product
Table 141. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 142. AstraZeneca Recent Developments
Table 143. Mylan Company Details
Table 144. Mylan Business Overview
Table 145. Mylan Non-oncology Biopharmaceuticals Product
Table 146. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 147. Mylan Recent Developments
Table 148. LEO Pharma Company Details
Table 149. LEO Pharma Business Overview
Table 150. LEO Pharma Non-oncology Biopharmaceuticals Product
Table 151. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 152. LEO Pharma Recent Developments
Table 153. Boehringer Ingelheim Company Details
Table 154. Boehringer Ingelheim Business Overview
Table 155. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product
Table 156. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 157. Boehringer Ingelheim Recent Developments
Table 158. Alexion Pharmaceuticals Company Details
Table 159. Alexion Pharmaceuticals Business Overview
Table 160. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product
Table 161. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 162. Alexion Pharmaceuticals Recent Developments
Table 163. Elusys Therapeutics Company Details
Table 164. Elusys Therapeutics Business Overview
Table 165. Elusys Therapeutics Non-oncology Biopharmaceuticals Product
Table 166. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 167. Elusys Therapeutics Recent Developments
Table 168. Swedish Orphan Biovitrum Company Details
Table 169. Swedish Orphan Biovitrum Business Overview
Table 170. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product
Table 171. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 172. Swedish Orphan Biovitrum Recent Developments
Table 173. Biogen Company Details
Table 174. Biogen Business Overview
Table 175. Biogen Non-oncology Biopharmaceuticals Product
Table 176. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 177. Biogen Recent Developments
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Non-oncology Biopharmaceuticals Market Share by Type: 2023 VS 2030
Figure 3. Biologics Features
Figure 4. Biosimilars Features
Figure 5. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Application: 2023 VS 2030
Figure 7. Immunology Case Studies
Figure 8. Endocrinology Case Studies
Figure 9. Others Case Studies
Figure 10. Non-oncology Biopharmaceuticals Report Years Considered
Figure 11. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Region: 2023 VS 2030
Figure 14. Global Non-oncology Biopharmaceuticals Market Share by Players in 2023
Figure 15. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2023
Figure 17. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 19. North America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 20. North America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)
Figure 21. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 24. Europe Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 25. Europe Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 26. Europe Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)
Figure 27. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. China Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 34. China Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 35. China Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 36. Asia Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 37. Asia Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 38. Asia Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 39. Asia Non-oncology Biopharmaceuticals Market Share by Region (2019-2030)
Figure 40. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. China Taiwan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)
Figure 48. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)
Figure 49. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)
Figure 50. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Israel Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. GCC Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 57. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 58. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 59. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 60. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 61. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 62. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 63. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 64. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 67. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 68. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 69. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 70. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 71. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 72. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 73. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 74. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 75. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 76. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 77. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 78. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Medical Waste Fluid Solidifier Market Research Report 2025
Jun 12, 25
Global Metalized Bubble Material Market Research Report 2025
Jun 12, 25
Global 70% Isopropyl Rubbing Alcohol Market Research Report 2025
Jun 12, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232